Cardiac Resynchronization Therapy Market By Product Type (CRT-P, CRT-D); By Application (Heart Failure with Reduced Ejection Fraction, Atrial Fibrillation, Post-Myocardial Infarction); By End User (Hospitals, Ambulatory Surgical Centers, Cardiologists & Clinics, Contract Research Organizations); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Cardiac Resynchronization Therapy Market: CRT Demand Moves Toward Upgrade Procedures, Leadless Pacing and Physiologic Resynchronization (Last Updated on: June-2026)

The Global Cardiac Resynchronization Therapy (CRT) Market is set to grow from USD 9.1 billion in 2024 to USD 14.5 billion by 2030, at a robust 8.2% CAGR.

 

The Cardiac Resynchronization Therapy Market is evolving from standard biventricular pacing into a more selective cardiac device market shaped by heart failure screening, electrophysiology access, CRT-P/CRT-D selection, upgrade procedures, and next-generation pacing strategies.

 

Heart failure creates the demand base. More than 64 million people live with heart failure globally, while the United States has about 6.7 million adults aged 20 years and older with heart failure, projected to reach 8.5 million by 2030. CRT does not address the full heart failure population. Its strongest role is in patients with reduced ejection fraction, left bundle branch block, wide QRS duration, persistent symptoms despite medical therapy, atrial fibrillation with high pacing dependence, or post-infarction ventricular dysfunction that creates device-level risk. [Centers for Disease Control and Prevention]

 

The commercial opportunity is not simply more heart failure prevalence. It is the ability of cardiology systems to identify device-eligible patients earlier and move them into electrophysiology-led resynchronization care before repeated hospitalization, pacing-induced decline, or late-stage disease progression.

 

Eligibility and Treatment Pathway

CRT demand begins when heart failure care becomes a pacing decision. The strongest candidates are patients with reduced left ventricular function and delayed ventricular activation because CRT directly targets mechanical dyssynchrony. ECG interpretation, QRS duration, LBBB morphology, echocardiographic assessment, and symptom classification therefore act as commercial filters.

A major market gap remains between diagnosis and implantation. Some patients stay on medical therapy without timely CRT evaluation. Others receive conventional pacemakers or ICDs before long-term ventricular synchrony is considered. In atrial fibrillation, the opportunity is more selective and depends on maintaining high biventricular pacing, especially after AV node ablation or in high-pacing-burden settings.

This makes CRT an infrastructure-dependent market. Device revenue follows centers that can screen patients, perform complex implants, manage upgrades, troubleshoot non-response, and support remote monitoring after discharge.

 

Cardiac Resynchronization Therapy Market Segment Analysis

By product type, CRT-D remains the higher-value segment because it combines ventricular resynchronization with defibrillator protection. It is most relevant in patients with reduced ejection fraction who meet CRT criteria and also carry meaningful sudden cardiac death risk. Adoption depends on ICD eligibility, arrhythmic risk, survival benefit, comorbidity profile, and payer approval.

CRT-P has a more selective but durable role. It is used when coordinated ventricular pacing is needed without defibrillator escalation. Accordingly, CRT-P is important in older patients, frail patients, lower arrhythmic-risk patients, and cases where shock therapy adds limited incremental value. The segment is smaller than CRT-D but remains important because many patients need synchrony, not full defibrillator protection.

By application, heart failure with reduced ejection fraction is the core demand pool. HFrEF patients with LBBB and wide QRS duration represent the clearest clinical and commercial target because CRT can improve ventricular coordination, reverse remodeling, and reduce deterioration in properly selected patients.

Atrial fibrillation is a specialist-use segment rather than a broad CRT indication. Its relevance appears when AF patients also have heart failure, AV node ablation, or high pacing burden, where a high percentage of biventricular pacing becomes essential.

Post-myocardial infarction demand is also indirect. CRT is not used simply because a patient had an MI. The opportunity appears when post-MI remodeling leads to ischemic cardiomyopathy, reduced ejection fraction, conduction delay, or high sudden-death risk. In this group, CRT-D can become more relevant because both resynchronization and defibrillator protection may be justified.

 

What Is Moving CRT Adoption

CRT adoption is being pulled by patients already visible inside cardiology care but not always moved into device evaluation early enough. The highest-value opportunity sits in HFrEF patients with LBBB, wide QRS duration, persistent symptoms, or rising pacing burden after pacemaker/ICD implantation. These are not unknown patients. They are often already in echo, ECG, heart failure, or device-clinic workflows.

Upgrade procedures are also gaining importance, as chronic right ventricular pacing can contribute to ventricular dysfunction in selected patients. For device manufacturers, this represents a more defined commercial pathway than new patient identification, as these individuals already have established implant histories, structured follow-up data, and a clear route back into electrophysiology care.

The main performance gap remains CRT non-response. Benefit can weaken when LV lead placement is poor, myocardial scar is extensive, atrial fibrillation reduces biventricular pacing, or programming is not optimized. This is why leadless LV pacing, left bundle branch area pacing, remote diagnostics, and better upgrade tools are commercially relevant. They target the reasons CRT fails in practice, not just the reasons CRT is prescribed. [Brandon Capital]

The adoption barrier is procedural depth. CRT requires more than device availability. It needs operator skill, coronary sinus access, lead management, device programming, and post-implant surveillance. Markets with weak EP capacity will remain underpenetrated even if heart failure prevalence is high.

 

Leadless CRT and Physiologic Pacing

The strongest technology shift is the move beyond dependence on conventional coronary sinus LV leads. Traditional CRT can be limited by difficult venous anatomy, failed lead placement, high thresholds, lead instability, phrenic nerve stimulation, infection history, or high-risk upgrade scenarios.

The WiSE CRT System addresses this gap by enabling leadless left ventricular endocardial pacing in adult patients who meet CRT criteria but cannot receive or maintain a conventional coronary sinus lead, or who are high-risk upgrade candidates. It is not a mass-market replacement for standard CRT. Its value is concentrated in patients who were previously difficult to treat or functionally excluded from conventional CRT. [MassDevice]

Left bundle branch area pacing is the second major shift. Instead of pacing around dyssynchrony through conventional biventricular stimulation, LBBAP attempts to recruit the heart’s native conduction system more directly. If evidence continues to support better electrical resynchronization and fewer heart failure events in selected patients, CRT competition will move toward physiologic pacing capability.

These technologies change the market from a two-product discussion into a broader resynchronization strategy: conventional biventricular pacing, leadless LV pacing, and conduction-system-based pacing.

 

North America Cardiac Resynchronization Therapy Market

North America remains the most attractive CRT market because it combines a large heart failure burden with mature electrophysiology infrastructure, payer coverage, advanced implant centers, remote monitoring adoption, and strong cardiac rhythm device company presence.

The United States has a large installed cardiac implantable electronic device base, with more than 300,000 new CIED implants performed annually. This matters because CRT growth increasingly comes from patients already under device surveillance, including pacemaker and ICD patients who later require resynchronization upgrades. [MDPI] [National Institutes of Health]

North America is better positioned for advanced CRT because its high-volume EP centers already manage the hardest cases: failed LV leads, CRT upgrades, atrial fibrillation with pacing dependence, and non-response workups. This makes the region more receptive to leadless CRT and conduction-system pacing, where adoption depends on procedural confidence rather than device availability alone.

The North America opportunity is therefore value-led rather than volume-led. The market rewards higher-complexity implants, upgrade pathways, remote monitoring, and technologies that reduce failed procedures or improve CRT response.

 

Competitive Landscape and Device Innovation

The CRT market is concentrated around cardiac rhythm management companies with strong device ecosystems. Medtronic, Abbott, Boston Scientific, BIOTRONIK, MicroPort, and EBR Systems are the most relevant players.

Medtronic benefits from scale across pacing, ICD, CRT systems, leads, monitoring, and conduction-system pacing tools. Abbott remains important across ICD, CRT-D, pacing, and remote monitoring. Boston Scientific is positioned through CRT-D and ICD platforms, with strength in device longevity and rhythm management. BIOTRONIK is relevant through CRT-D and pacing systems, including platforms aligned with left bundle branch area pacing workflows. EBR Systems is differentiated through WiSE CRT, giving it a focused position in leadless LV endocardial pacing. [Abbott Cardiovascular] [Biotronik]

 

Market Outlook

The Cardiac Resynchronization Therapy Market is entering a more selective growth phase. The strongest opportunities will come from patient conversion, CRT upgrades, response optimization, and technologies that make resynchronization possible in patients poorly served by conventional lead-based systems.

Future growth will depend less on broad device availability and more on measurable clinical performance. Hospitals will prefer systems that reduce failed procedures, simplify upgrades, extend device life, support remote follow-up, and improve the likelihood of reverse remodeling. Payers will continue to reward CRT when documentation shows clear eligibility and when the device choice matches clinical risk.

CRT is mature as a therapy, but the market is still changing. The next competitive phase will favor companies that combine reliable hardware, pacing innovation, electrophysiology workflow support, and evidence that their systems improve real heart failure outcomes.

 

Cardiac Resynchronization Therapy (CRT) Market Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 9.1 Billion
Revenue Forecast in 2030	USD 14.5 Billion
Overall Growth Rate	CAGR of 8.2% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	CRT-P, CRT-D
By Application	Heart Failure with Reduced Ejection Fraction, Atrial Fibrillation, Post-Myocardial Infarction
By End User	Hospitals, Ambulatory Surgical Centers, Cardiologists & Clinics, Contract Research Organizations
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., UK, Germany, China, India, Japan, Brazil, etc.
Market Drivers	Rising heart failure incidences Technological advancements Increasing awareness and adoption in emerging markets
Customization Option	Available Upon Request